Galina Selivanova

Overview

Best Publications

• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  Vladimir J.N. Bykov;Natalia Issaeva;Alexandre Shilov;Monica Hultcrantz

  1331
  Citations

• Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

  Natalia Issaeva;Przemyslaw Bozko;Martin Enge;Marina Protopopova

  972
  Citations

• Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.

  Galina Selivanova;Violetta Iotsova;Violetta Iotsova;Ismail Okan;Michael Fritsche

  504
  Citations

• EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins

  Laszlo Szekely;Galina Selivanova;Kristinn P. Magnusson;George Klein

  426
  Citations

• Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction.

  Mariam Grigorian;Susanne Andresen;Eugene Tulchinsky;Marina Kriajevska

  398
  Citations

• p53 binds single stranded DNA ends and catalyzes DNA renaturation and strand transfer

  G Bakalkin;T Yakovleva;G Selivanova;K P Magnusson

  393
  Citations

• Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

  Dawei Xu;Qian Wang;Astrid Gruber;Magnus Björkholm

  359
  Citations

• Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs

  Vladimir J. N. Bykov;Natalia Issaeva;Nicole Zache;Alexandre Shilov

  298
  Citations

• PRIMA-1 MET synergizes with cisplatin to induce tumor cell apoptosis

  Vladimir J N Bykov;Nicole Zache;Helene Stridh;Jacob Westman

  278
  Citations

• Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

  G Selivanova;K G Wiman

  243
  Citations

• p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain

  Georgy Bakalkin;Galina Selivanova;Tatjana Yakovleva;Elena Kiseleva

  240
  Citations

• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

  Thomas M Rippin;Vladimir J N Bykov;Stefan M V Freund;Galina Selivanova

  234
  Citations

• ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis

  Y Shi;F Nikulenkov;J Zawacka-Pankau;H Li

  225
  Citations

• Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

  Vladimir J.N. Bykov;Natalia Issaeva;Galina Selivanova;Klas G. Wiman

  222
  Citations

• Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis

  F. Nikulenkov;C. Spinnler;H. Li;C. Tonelli

  213
  Citations

• Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

  Natalia Issaeva;Assaf Friedler;Przemyslaw Bozko;Klas G. Wiman

  199
  Citations

• Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain

  Galina Selivanova;Ludmila Ryabchenko;Emmelie Jansson;Violetta Iotsova

  198
  Citations

• MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.

  Martin Enge;Wenjie Bao;Elisabeth Hedström;Stephen P. Jackson

  194
  Citations

• p53: a cell cycle regulator activated by DNA damage.

  Galina Selivanova;Klas G. Wiman

  172
  Citations

• APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

  Xiaoxiao Peng;Mei-Qiong-Zi Zhang;Francesca Conserva;Gihan Hosny

  164
  Citations